Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

NCT07212933 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT07212933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07212933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 1, 2025
Completion date
June 30, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biological therapy, gastric (stomach) cancer, immunotherapy